Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Galapagos NV published its annual report for the financial year 2018.
Annual Report 2018 is available for download on the Pharming website
Supporters and those opposed to the proposal are marshaling their forces ahead of the April 12 shareholder vote.
The South San Francisco cuts are not surprising, given that in December the company was forced to halt a Phase III study of Rova-T.
Microbix Biosystems Inc., an innovator of biological products and technologies, announces the voting results from the Annual Meeting of Shareholders which was held on March 27, 2019.
$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1
Probiodrug AG announced its financial results for the twelve-month period ending December 31, 2018, prepared in accordance with German GAAP and on a voluntary basis, in accordance with IFRS as endorsed by the European Union.
Durham, NC-based Precision BioSciences set its initial public offering (IPO) price at $16 per share, raising $126.4 million. It began trading today on the Nasdaq under the ticker symbol DTIL.
The rumors speculated that AstraZeneca planned to acquire Aveo in the second quarter of this year in order to gain the company’s kidney cancer drug, Tivozanib.
GeoVax Labs, Inc., a biotechnology company developing human vaccines, announced its financial results for the year ended December 31, 2018.